Arcellx Announces Presentation of Positive Clinical Results from Ongoing Phase 1 Study of CART-ddBCMA at the 2021 ASCO Annual Meeting

NEXT STORY
TRACON Pharmaceuticals Presents Data from a Phase 1 Study of Uliledlimab (TJ004309) and Tecentriq® (Atezolizumab) at the American Society of Clinical Oncology Virtual Annual Meeting
PREV STORY
Immunoassay Market Worth $46.5 Billion by 2028, Growing at a CAGR of 7.5% From 2021- Exclusive Report by Meticulous Research®
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Summit Appoints Dr David Roblin as Chief Operating Officer and President of Research & Development

Summit Therapeutics plc('Summit', 'Company' or the 'Group') SUMMIT APPOINTS DR DAVID ROBLIN AS CHIEF ...

author_avatar
NASDAQ Market News

Kiniksa Reports Data for Mavrilimumab in COVID-19 Pneumonia and Hyperinflammation and for Vixarelimab in Diseases Characterized by Chronic Pruritus

author_avatar
NASDAQ Market News

Progenics Pharmaceuticals Announces Presentation at the International Conference on Immunotherapy Radiotherapy Combinations

author_avatar
NASDAQ Market News